Ernexa Therapeutics ERNA

Ernexa Therapeutics Inc. is a preclinical stage synthetic allogeneic iMSC therapy company focused on developing off the shelf cell therapies for cancer and autoimmune diseases using induced pluripotent stem cell derived mesenchymal stem cells.

The company generates revenue primarily through potential future product sales, licensing agreements, and collaborations, including upfront and milestone payments from partners such as Factor Bioscience Limited under its exclusive license agreement.

The company operates through the following segments: therapeutic development and strategic partnerships.

• Therapeutic Development: This segment encompasses the research and preclinical development of product candidates such as ERNA-101 (interleukin 7 and interleukin 15 secreting iMSCs) for platinum resistant ovarian cancer and ERNA-201 (interleukin 10 secreting iMSCs) for autoimmune disorders like rheumatoid arthritis, leveraging the company’s synthetic iMSC platform.

• Strategic Partnerships: This segment involves collaborations with external entities, including the license and collaboration agreement with Factor Bioscience Limited, joint development efforts with academic institutions such as the University of Texas MD Anderson Cancer Center, and pursuit of research grants and partnerships to expand development capabilities and secure non dilutive funding.

Ernexa Therapeutics Inc. occupies an early stage niche in the regenerative medicine sector, competing with established MSC based therapy developers such as Mesoblast, BrainStorm Cell Therapeutics, and others, while leveraging its proprietary iMSC technology to differentiate through scalable, off the shelf manufacturing and targeted cytokine secretion.

The company serves patients and healthcare providers in the oncology and autoimmune disease markets, with current focus on individuals with platinum resistant ovarian cancer and rheumatoid arthritis, though specific customer names are not disclosed.